Date: 2017-05-30
Type of information: Opening of new premises
Compound: cGMP facility in Karlskoga (Sweden)
Company: Cambrex (USA - NJ)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On May 30, 2017, Cambrex announced that it has expanded large scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden and has introduced additional continuous flow manufacturing for the production of high purity intermediates.
- The expansion includes the installation of new multi-purpose reactors ranging from 4m3 to 12m3 and upgrading of the control room within an existing plant on site. This extra capacity increases the large scale manufacturing capabilities of the Karlskoga facility, which supports clients’ development projects from R&D through to large scale commercial manufacturing. Installation of all new equipment, including a 9m³ hydrogenation reactor, is expected to be completed by Q3 2017.
- In addition to the capacity investment at the Karlskoga site, Cambrex has introduced a dedicated continuous flow production unit, capable of producing multiple metric tons of high purity intermediates per annum.
- • On September 6, 2016, Cambrex announced a SEK 72 million ($9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in Sweden.
- The new facilities will undergo validation and cGMP qualification ahead of the operational startup in Q4 2016. The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to invest in small molecule API manufacturing across its global network of facilities.
Financial terms:
Latest news:
Is general: Yes
